Abstract
Background aims
Chimeric antigen receptor (CAR) T cell is a novel therapy for relapse and refractory
hematologic malignancy. Characteristics of CAR T cells are associated with clinical
efficacy and toxicity. The type of serum supplements used during cultivation affects
the immunophenotype and function of viral-based CAR T cells. This study explores the
effect of serum supplements on nonviral piggyBac transposon CAR T-cell production.
Methods
PiggyBac CD19 CAR T cells were expanded in cultured conditions containing fetal bovine
serum, human AB serum or xeno-free serum replacement. We evaluated the effect of different
serum supplements on cell expansion, transduction efficiency, immunophenotypes and
antitumor activity.
Results
Xeno-free serum replacement exhibited comparable CAR surface expression, cell expansion
and short-term antitumor activity compared with conventional serum supplements. However,
CAR T cells cultivated with xeno-free serum replacement exhibited an increased naïve/stem
cell memory population and better T-cell expansion after long-term co-culture as well
as during the tumor rechallenge assay.
Conclusions
Our study supports the usage of xeno-free serum replacement as an alternative source
of serum supplements for piggyBac-based CAR T-cell expansion.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.American journal of hematology. 2019; 94: S3-S9
- Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.Archives of pharmacal research. 2019; 42: 607-616
- Early and late hematologic toxicity following CD19 CAR-T cells.Bone marrow transplantation. 2019; 54: 1643-1650
- The market for chimeric antigen receptor T cell therapies.Nature reviews Drug discovery. 2018; 17: 161
- GMP CAR-T cell production.Best Practice & Research Clinical Haematology. 2018; 31: 126-134
- piggyBac-ing models and new therapeutic strategies.Trends in biotechnology. 2015; 33: 525-533
- PiggyBac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts.Molecular Therapy. 2018; 26: 1883-1895
- Enhanced expression of anti-CD19 chimeric antigen receptor in piggyBac transposon-engineered T cells.Molecular Therapy-Methods & Clinical Development. 2018; 8: 131-140
- Guidance on good cell culture practice: a report of the second ECVAM task force on good cell culture practice.Alternatives to Laboratory Animals. 2005; 33: 261-287
- A consensus introduction to serum replacements and serum-free media for cellular therapies.Cytotherapy. 2017; 19: 155-169
- Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells.Cytotherapy. 2014; 16: 170-180
- Human serum and platelet lysate are appropriate xeno-free alternatives for clinical-grade production of human MuStem cell batches.Stem cell research & therapy. 2018; 9: 1-20
- Comparison of human serum with fetal bovine serum for expansion and differentiation of human synovial MSC: potential feasibility for clinical applications.Cell transplantation. 2008; 17: 549-557
- Human platelet lysate efficiency, stability, and optimal heparin concentration required in culture of mammalian cells.Blood research. 2020; 55: 35
- Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.Journal for immunotherapy of cancer. 2019; 7: 1-15
- Human platelet lysate media supplement supports lentiviral transduction and expansion of human T lymphocytes while maintaining memory phenotype.Journal of immunology research. 2019; 2019
- Enhancing chimeric antigen receptor T cell anti-tumor function through advanced media design.Molecular Therapy-Methods & Clinical Development. 2020; 18: 595-606
- Improved expansion and in vivo function of patient T cells by a serum-free medium.Molecular Therapy-Methods & Clinical Development. 2018; 8: 65-74
- Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.Cytotherapy. 2018; 20: 941-951
- Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy.Cancers. 2016; 8: 36
- Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15.Blood, The Journal of the American Society of Hematology. 2014; 123: 3750-3759
- T cell maturation stage prior to and during GMP processing informs on CAR T cell expansion in patients.Frontiers in immunology. 2016; 7: 648
- Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS immune cell serum replacement.Clinical & translational immunology. 2015; 4: e31
- Xeno-free serum replacement for ex vivo culture and expansion of T cells.Journal for ImmunoTherapy of Cancer. 2014; 2 (1-)
- Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype.Molecular Therapy-Methods & Clinical Development. 2021; 21: 315-324
- Naive human T cells can be a source of IL-4 during primary immune responses.Clinical and Experimental Immunology. 2001; 118: 384-391
- Promotion of human T lymphocyte proliferation by IL-4.The Journal of Immunology. 1989; 142: 1548-1557
- Biological properties of human interleukin-4.(editors)in: Freund M Link H Welte K Cytokines in hemopoiesis, oncology, and AIDS. Springer, Berlin, Heidelberg1990: 287-291
- Evaluation of nonviral piggybac and lentiviral vector in functions of CD19chimeric antigen receptor T cells and their antitumor activity for CD19+ tumor cells.Frontiers in immunology. 2022; 12802705
- CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment?.Journal of immunology research. 2015; 2015
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.Nature. 1999; 401: 708-712
Article info
Publication history
Published online: December 13, 2022
Accepted:
November 27,
2022
Received:
July 27,
2022
Identification
Copyright
© 2022 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.
